A big thank you to Lilly who join the sponsors of Glycosmedia via an educational grant
Please contact the Editor-in-chief Jim Young for sponsorship details
Alterations of platelet biochemical and functional properties in newly diagnosed type 1 diabetes: a role in cardiovascular risk?
T1D patients exhibit structural and functional modifications of platelet membrane properties and alterations of NO metabolism due to diabetes per se and not to chronic hyperglycemia, insulin therapy or ageing. These results support the hypothesis that oxidative attack could be an important early event in the pathogenesis of diabetic complications (Diabetes/Metabolism Research and Reviews)
Expansion of CD4+CD28null T-lymphocytes in diabetic patients: exploring new pathogenetic mechanisms of increased cardiovascular risk in diabetes mellitus
In DM patients, CD4+CD28nullT-cells are expanded and are associated with poor glycaemic control; they also correlate with the occurrence of a first cardiovascular event and with a worse outcome after an ACS (European Heart Journal)
New IDF newsletter on the UN Summit on NCDs
A new monthly newsletter on the UN High-Level Summit on Non-Communicable Diseases (NCDs), which will be published throughout 2011 (International Diabetes Federation)
Investigating concordance in diabetes diagnosis between primary care charts (electronic medical records) and health administrative data: a retrospective cohort study
This study establishes the feasibility of developing an electronic medical record standard definition of diabetes and validates an algorithm for use in this context (BMC Health Services Research)
Effect of Automated Bio-Behavioral Feedback on the Control of Type 1 Diabetes
Feedback of SMBG data and summary SMBG-based measures resulted in improvement in average glycemic control and reduction in moderate/severe hypoglycemia (Diabetes Care)
Systematic review of communication technologies to promote access and engagement of young people with diabetes into healthcare
While communication technologies may increase the frequency of contact between patient and health care professional, it remains unclear whether this results in improved outcomes and is often the basis of the intervention itself (BMC)
Renal glucose reabsorption inhibitors to treat diabetes
This review examines the potential of SGLT2 inhibitors as a novel approach to the treatment of hyperglycaemia in T2DM (Trends in Pharmacological Sciences)
Signaling diversity of PKA achieved via a Ca2+-cAMP-PKA oscillatory circuit
Here, we show that protein kinase A (PKA), Ca2+ and cyclic AMP (cAMP) oscillate in sync in insulin-secreting MIN6 beta cells, forming a highly integrated oscillatory circuit – Abstract (Nature Chemical Biology)
Closed-Loop Insulin Delivery During Pregnancy Complicated by Type 1 Diabetes
Model predictive control (MPC) algorithm performance was maintained throughout pregnancy, suggesting that overnight closed-loop insulin delivery could be used safely during pregnancy. More work is needed to achieve optimal postprandial glucose control (Diabetes Care)
Lilly and Boehringer Ingelheim Announce Strategic Alliance to Bring New Diabetes Treatments to Patients Worldwide
Eli Lilly and Company and Boehringer Ingelheim today announced a global agreement to jointly develop and commercialize a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two oral diabetes agents—linagliptin and BI10773—as well as Lilly’s two basal insulin analogues—LY2605541 and LY2963016—as well as the option to co-develop and co-commercialize Lilly’s anti-TGF-beta monoclonal antibody (Lilly)
Novartis gains new indication for Lucentis
Novartis gains new indication for Lucentis in EU for vision loss due to Diabetic Macular Edema, a leading cause of blindness (Novartis)
MannKind CEO bets big on diabetes drug
MannKind Corp. Chief Executive Alfred Mann has poured a considerable amount of his personal fortune into developing the company’s inhaled insulin treatment for diabetes, contributing well over half of the $1.5 billion invested in the drug so far (MarketWatch)
Glycosmedia is also available as an App: